A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects
Status:
COMPLETED
Trial end date:
2025-09-17
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.
Phase:
PHASE4
Details
Lead Sponsor:
Bun Yao Biotechnology Co., Ltd
Collaborators:
Clinny biotech limited Taipei Veterans General Hospital, Taiwan